from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A particular narcotic painkiller.


Sorry, no etymologies found.


  • A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the second half of 2011 under a grant from the US Army Medical Research and Material Command.

  • I am convinced of the tremendous opportunity afforded by the AcelRx sufentanil NanoTab technology in treating both post-operative pain and other acute and breakthrough pain conditions.

  • Although the analgesic efficacy of sufentanil has been well established, its use has been limited due to its short IV plasma half-life.


  • Oct. 30/PRNewswire/-- AcelRx Pharmaceuticals, Inc. today announced that it has successfully completed an End-of-Phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company's proprietary NanoTab (TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.


  • In the NanoTab oral transmucosal dosage form, sufentanil demonstrates a therapeutically appropriate pharmacokinetic profile for post-operative PCA usage.


  • TRANSDUR-Sufentanil is our proprietary transdermal patch intended to provide sufentanil to chronic pain sufferers for a period of up to seven days from a single application.


  • ARX-03 is based on the AcelRx's proprietary NanoTab (TM) dosage form, which enables delivery of the sufentanil/triazolam combination by the oral transmucosal route, resulting in high drug bioavailability but significantly lower and safer peak plasma levels than the intravenous route.

    Health News from Medical News Today

  • We have the potential for future business development deals with ELADUR, with the sufentanil patch in Europe and Asia, POSIDUR in Asia, as well as other we've programs yet to disclose.

    Healthcare Sector and Stocks Analysis from Seeking Alpha

  • The second quarter was highlighted by the on-schedule submission of our Remoxy NDA, progress in our POSIDUR regulatory discussions, the orphan drug designation for bupivacaine for PHN, which is relevant to our ELADUR program, Endo's new senior management beginning to communicate with regard to the development timing of our seven day sufentanil patch, and the elimination of our convert in the subsequent reduction of our corporate debt from over $24 million to less than $600,000.

    Healthcare Sector and Stocks Analysis from Seeking Alpha


Log in or sign up to get involved in the conversation. It's quick and easy.